27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
Observational studies and pilot trials suggest that metformin may help prevent cognitive decline in neurodegenerative disorders. 3 key findings →
Participants: 326 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
AN1792 + QS-21 elicited a positive antibody response to Abeta42 in more than half of this elderly study population. 2 key findings →
Design: clinical trial Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
In 1999, 17.7% (95% confidence interval [CI], 17.2-18.1) of patients with dementia were using atypical or conventional antipsychotics. 3 key findings →
Participants: 254 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Parkinson's disease (PD), dementia with Lewy bodies and multiple system atrophy, collectively referred to as synucleinopathies, are associated with a diverse group of genetic and environmental susceptibilities. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Disorders characterized by α-synuclein (α-syn) accumulation, Lewy body formation and parkinsonism (and in some cases dementia) are collectively known as Lewy body diseases. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Hexanucleotide expansions in C9ORF72 are the most frequent genetic cause of amyotrophic lateral sclerosis and frontotemporal dementia. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The use of anticholinergic medications among patients with OAB was associated with an increased risk of new-onset dementia compared to beta-3 agonist users. 5 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source
Amyloid-related imaging abnormalities (ARIA) are the principal safety concern limiting anti-amyloid therapies for Alzheimer's disease, yet their biology remains unclear. 3 key findings →
Design: case-control Participants: 3 Evidence: preliminary
Full summary, score breakdown and related studies → Original source Free full text
Selegiline, an inhibitor of monoamine oxidase B, was tested on patients with mild to moderate dementia of the Alzheimer type. 2 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Of 482 participants in the safety population, 140 of 158 participants (88.6%) assigned to placebo, 117 of 166 participants (70.5%) to 224 mg of edonerpic maleate, and 120 of 158 participants (76.0%) to 448 mg of edonerpic maleate completed the trial. 1 key finding →
Design: clinical trial Participants: 482 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Elderly people taking anticholinergic drugs were at increased risk for cognitive decline and dementia. 5 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
ARIA monitoring is important to inform treatment dosing decisions and might be improved through assistive software. 4 key findings →
Participants: 16 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
This review provides a comprehensive state-of-the-art conceptual review of radiological features, clinical detection and classification challenges, pathophysiology, underlying biological mechanism(s) and risk factors/predictors associated with ARIA. 2 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source
In this single-dose study, aducanumab demonstrated an acceptable safety and tolerability profile and linear PK at doses ≤30 mg/kg (clinicaltrials.govNCT01397539). 2 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source
Our case suggests that ischemic strokes may be a feature of ARIA and highlights the importance of having a high clinical suspicion for seizures in ARIA. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Recent Phase 3 clinical trials have demonstrated its ability to reduce brain amyloid-β (Aβ) load and slow cognitive decline in patients with early Alzheimer's disease (AD). 4 key findings →
Design: clinical trial Participants: 811 Evidence: low
Full summary, score breakdown and related studies → Original source
Our study suggests that SSAE-3 and SSAE-5 are valid ARIA-E rating scales for use in routine clinical practice by experienced radiologists in specialized settings. 4 key findings →
Participants: 75 Evidence: low
Full summary, score breakdown and related studies → Original source
Among nursing home residents with dementia, discontinuing long-term antipsychotic medication use was associated with lower risks of hospitalization, pneumonia, and urinary tract infections, suggesting clinical benefits in this population. 4 key findings →
Design: cohort Participants: 4,222 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Serious events, as indicated by a hospital admission or death, are frequent following the short-term use of antipsychotic drugs in older adults with dementia. 2 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
TDP-43 and FUS are RNA-binding proteins that form cytoplasmic inclusions in some forms of amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD). 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Caregivers and neurologists considered incremental clinical benefit over SOC and safety to be highly desirable qualities for a new drug that could clear amyloid plaques and delay clinical progression and indicated a willingness to accept incremental ARIA-E to achieve additional clinical benefits. 2 key findings →
Participants: 137 Evidence: low
Full summary, score breakdown and related studies → Original source
After taking into consideration a possible protopathic bias in the 2 years preceding the AD diagnosis date, benzodiazepine use was not associated with an increased risk of developing AD. 4 key findings →
Design: case-control study Evidence: moderate
Full summary, score breakdown and related studies → Original source
SSAE-3/5 scores correlated with BGTS scores, with high inter-reader intraclass correlation coefficients across all scales. 3 key findings →
Participants: 75 Evidence: low
Full summary, score breakdown and related studies → Original source
Overall, 304 patients receiving cholinesterase inhibitors/memantine also received anticholinergics. 5 key findings →
Participants: 304 Evidence: low
Full summary, score breakdown and related studies → Original source
Read the article, “Behavioral and Psychological Symptoms of Dementia: How Long Does Every Behavior Last, and Are Particular Behaviors Associated With PRN Antipsychotic Agent Use?” found on pages 22–37, carefully noting any tables and other illustrative materials that are included to enhance your knowledge and understanding of the content. 5 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source
8 of the 468 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 8. The same 8 appear here every time.
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →